MCID: PRT037
MIFTS: 65

Pertussis

Categories: Infectious diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 74 52 58 3 15 71
Whooping Cough 12 74 52 58 42 3 15 17 32
Bordetella Infections 43 17 71
Whooping Cough Due to Unspecified Organism 71
Bordetella Pertussis Infection 52
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

58
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
MeSH 43 D001885
SNOMED-CT 67 26484003
MESH via Orphanet 44 D014917
ICD10 via Orphanet 33 A37.0 A37.1 A37.8 more
UMLS via Orphanet 72 C0043167 C0043168
Orphanet 58 ORPHA1489
UMLS 71 C0006015 C0043167 C0043168

Summaries for Pertussis

MedlinePlus : 42 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to tetanus and haemophilus influenzae, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Pertussis and Signaling by GPCR. The drugs Montelukast and Iron have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, neutrophil and smooth muscle, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

CDC : 3 Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Wikipedia : 74 Whooping cough, also known as pertussis or 100-day cough, is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 754)
# Related Disease Score Top Affiliating Genes
1 tetanus 32.5 TNF IL6 IL1B IL10
2 haemophilus influenzae 31.9 TNF CXCL8
3 cholera 31.6 TNF IL6 GNAI1 FOS CXCL8 ADCY10
4 measles 31.4 TNF TLR4 MYD88 IL6 IL1B
5 mumps 31.3 TNF IL6 IL10 CXCL8
6 allergic hypersensitivity disease 31.3 TNF TLR4 IL10 CXCL8
7 rubella 31.2 TNF TLR4 IL6 IL10 CALM1
8 pain agnosia 31.1 OPRM1 IL6 FOS
9 bronchiolitis 31.1 TNF TLR4 IL6 IL10 CXCL8
10 encephalitis 31.0 TNF IL6 IL1B IL10
11 typhoid fever 31.0 TNF TLR4 IL6 IL1B
12 chickenpox 31.0 TNF IL6 IL10
13 hepatitis a 31.0 TNF TLR4 IL10
14 neutrophil migration 31.0 MAPK1 ITGB2 ITGAM CXCL8
15 influenza 30.9 TNF MYD88 IL6 IL1B CXCL8
16 sudden infant death syndrome 30.9 TNF IL6 IL1B IL10 CXCL8
17 amebiasis 30.9 TNF TLR4 CXCL8
18 respiratory failure 30.9 TNF JUN IL6 IL1B IL10 CXCL8
19 pleurisy 30.9 TNF TLR4 CXCL8
20 post-transplant lymphoproliferative disease 30.9 TNF IL6 IL10
21 bronchopneumonia 30.9 TNF TLR4 IL6 IL10 CXCL8
22 lymphocytic choriomeningitis 30.8 MYD88 IL6 CXCL8
23 laryngitis 30.8 TNF IL6 IL1B
24 neuroblastoma 30.7 TNF OPRM1 MAPK1 JUN IL6 FOS
25 exanthem 30.7 TNF IL6 IL10 CXCL8
26 food allergy 30.7 TNF TLR4 IL10 CXCL8
27 autoimmune disease 30.7 TNF ITGAM IL6 IL1B IL10 CXCL8
28 allergic asthma 30.7 TLR4 ITGB2 ITGAM IL10 CXCL8
29 immune deficiency disease 30.7 TNF JUN ITGB2 IL6 IL10
30 bronchitis 30.7 TNF TLR4 IL6 IL1B IL10 CXCL8
31 hepatitis b 30.7 TNF TLR4 MYD88 IL6 CXCL8
32 sleep disorder 30.7 TNF IL6 FOS
33 meningoencephalitis 30.6 TNF IL6 IL10
34 autoimmune uveitis 30.6 TNF IL1B IL10
35 erythema multiforme 30.6 TNF IL6 CXCL8
36 morphine dependence 30.6 OPRM1 FOS ADCY10
37 uveitis 30.6 TNF IL6 IL10 CXCL8
38 orchitis 30.6 TNF IL6 IL10
39 thyroiditis 30.6 TNF IL6 IL10
40 chlamydia pneumonia 30.6 TNF TLR4 IL6 IL10 CXCL8
41 dermatitis 30.6 TNF TLR4 IL6 IL10 CXCL8
42 chlamydia 30.5 TNF TLR4 IL6 IL1B IL10 CXCL8
43 pneumonia 30.5 TNF TLR4 ITGAM IL6 IL1B IL10
44 human immunodeficiency virus type 1 30.5 TNF MAPK10 MAPK1 IL6 IL10
45 neuritis 30.5 TNF IL6 IL1B IL10 CXCL8
46 bacterial pneumonia 30.5 TNF TLR4 IL6 IL10 CXCL8
47 cellulitis 30.5 TNF IL6 IL10
48 otitis media 30.5 TNF TLR4 IL6 IL1B IL10 CXCL8
49 fibrosarcoma 30.5 TNF MAPK1 JUN FOS
50 pulmonary edema 30.5 TNF IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


fever, pruritus, snoring, coughing

GenomeRNAi Phenotypes related to Pertussis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CXCL8 IL10 IL1B JUN MYD88 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CXCL8 IL10 IL1B JUN MAPK1 MYD88

MGI Mouse Phenotypes related to Pertussis:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ADCY10 FOS GNAI1 GNAZ IL10 IL1B
2 hematopoietic system MP:0005397 10.35 FOS GNAI1 GNAZ IL10 IL1B IL6
3 cellular MP:0005384 10.31 ADCY10 FOS IL10 IL6 ITGAM ITGB2
4 behavior/neurological MP:0005386 10.3 FOS GNAI1 GNAZ IL10 IL6 JUN
5 cardiovascular system MP:0005385 10.25 ADCY10 IL10 IL1B IL6 ITGB2 JUN
6 immune system MP:0005387 10.25 FOS GNAI1 IL10 IL1B IL6 ITGAM
7 nervous system MP:0003631 10.17 FOS GNAI1 GNAZ IL10 IL1B IL6
8 integument MP:0010771 10.14 FOS GNAZ IL10 IL1B IL6 ITGB2
9 adipose tissue MP:0005375 10.08 FOS GNAI1 IL6 MYD88 OPRM1 TLR4
10 neoplasm MP:0002006 9.97 FOS IL10 IL1B IL6 MAPK1 MYD88
11 no phenotypic analysis MP:0003012 9.86 ADCY10 GNAI1 IL10 JUN MAPK10 MYD88
12 reproductive system MP:0005389 9.85 ADCY10 FOS GNAZ IL10 IL6 MAPK1
13 skeleton MP:0005390 9.7 FOS GNAI1 IL10 IL1B IL6 ITGB2
14 vision/eye MP:0005391 9.28 FOS IL10 IL6 ITGB2 JUN MAPK1

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
3
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
4
Pentetic acid Approved Phase 4 67-43-6
5
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
BCG vaccine Investigational Phase 4
8 Leukotriene Antagonists Phase 4
9 Vaccines Phase 4
10 Immunologic Factors Phase 4
11 Antitoxins Phase 4
12 Anti-Bacterial Agents Phase 4
13 Anti-Infective Agents Phase 4
14 Adjuvants, Immunologic Phase 4
15 Aluminum phosphate Phase 4
16 Chelating Agents Phase 4
17 Iron Chelating Agents Phase 4
18 Anticoagulants Phase 4
19 Calcium, Dietary Phase 4
20 Antidotes Phase 4
21 Micronutrients Phase 4
22 Trace Elements Phase 4
23 Nutrients Phase 4
24 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
25 Chrysanthemum Phase 4
26 Immunoglobulins Phase 4
27 Antibodies Phase 4
28
Deferiprone Approved Phase 3 30652-11-0 2972
29
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
30
tannic acid Approved Phase 3 1401-55-4
31
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
32
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
33 Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
34
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
35 Rho(D) Immune Globulin Phase 3
36 Immunoglobulins, Intravenous Phase 3
37 gamma-Globulins Phase 3
38 Hemagglutinins Phase 3
39 Cathartics Phase 3
40 Laxatives Phase 3
41 taxane Phase 3
42 Somatomedin B Phase 3
43 Fibrinolytic Agents Phase 3
44 Pharmaceutical Solutions Phase 3
45 Antibodies, Monoclonal Phase 3
46 Respiratory System Agents Phase 2, Phase 3
47 Anti-Asthmatic Agents Phase 2, Phase 3
48
Histidine Investigational, Nutraceutical Phase 2, Phase 3 71-00-1 6274
49
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
50
Ibuprofen Approved Phase 2 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 414)
# Name Status NCT ID Phase Drugs
1 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
2 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
3 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study Unknown status NCT02179996 Phase 4
5 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
6 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
7 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
8 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
9 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
10 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
11 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
12 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
13 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
14 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
15 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
16 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
17 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
18 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
19 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
20 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Completed NCT02408926 Phase 4
21 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
22 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
23 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
24 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
25 Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants Completed NCT01698346 Phase 4
26 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
27 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
28 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
29 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
30 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
31 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
32 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
33 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
34 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
35 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
36 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
37 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
38 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
39 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
40 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
41 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
42 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
43 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
44 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
45 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
46 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
47 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
48 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
49 A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. Completed NCT01250756 Phase 4
50 Evaluation of GSK Biologicals' Boostrix™ in Healthy Adults, 10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR
Guaifenesin

Cochrane evidence based reviews: bordetella infections

Genetic Tests for Pertussis

Anatomical Context for Pertussis

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

19
Respiratory Tract

MalaCards organs/tissues related to Pertussis:

40
Neutrophil, Smooth Muscle, Endothelial, Testes, T Cells, Brain, Lung

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 28285)
# Title Authors PMID Year
1
DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination. 61 42
31444785 2019
2
Neonatal Immunity to Bordetella pertussis Infection and Current Prevention Strategies. 61 42
30882004 2019
3
A pilot study of a novel, incentivised mHealth technology to monitor the vaccine supply chain in rural Zambia. 42
31448013 2019
4
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
5
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019. 61
31960801 2020
6
Using the North Dakota IIS to Assess the Response of Health Care Providers to the ACIP Recommendation for Tdap Vaccination During Pregnancy. 61
31834203 2020
7
Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. 61
32032310 2020
8
Two centuries of immunisation in the UK (part 1). 61
31272966 2020
9
Role of lysophosphatidic acid in vascular smooth muscle cell proliferation. 61
31369714 2020
10
Exploring bacterial pathogen community dynamics in freshwater beach sediments: A tale of two lakes. 61
31736260 2020
11
Routine Childhood Vaccines Given in the First 11 Months of Life. 61
31879133 2020
12
Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018. 61
31883809 2020
13
What Matters to Parents Regarding Immunization of Their Children: Systematic Analysis of Expert Advice to Parents in an Internet Forum. 61
31725113 2020
14
Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. 61
31948817 2020
15
A cost-effectiveness analysis of traditional and geographic information system-supported microplanning approaches for routine immunization program management in northern Nigeria. 61
31924428 2020
16
Expression and function of umami receptors T1R1/T1R3 in gastric smooth muscle. 61
31721379 2020
17
Prevention of chronic diseases in middle-age women: a cross-sectional study on an Italian large sample. 61
31263891 2020
18
Impact of Pertussis on the Italian population: Analysis of hospital discharge records in the period 2001-2014. 61
31678191 2020
19
Mandatory Vaccination in Europe. 61
31932361 2020
20
Update from the Advisory Committee on Immunization Practices. 61
32016424 2020
21
Beneficial role of simvastatin in experimental autoimmune myositis. 61
31863923 2020
22
π-Helix Controls Activity of Oxygen-Sensing Diguanylate Cyclases. 61
32039439 2020
23
Childhood infectious diseases and risk of non-Hodgkin's lymphoma according to the WHO classification: A reanalysis of the Italian multicenter case-control study. 61
31077355 2020
24
Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis. 61
31889607 2020
25
Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study. 61
31813648 2020
26
Timeliness and equity of infant pertussis vaccination in wales: Analysis of the three dose primary course. 61
31839466 2020
27
Structural and Functional Characterization of the Globin-Coupled Sensors of Azotobacter vinelandii and Bordetella pertussis. 61
31559835 2020
28
Vaccination during pregnancy: current and possible future recommendations. 61
31912233 2020
29
Development of a Pertactin-Coated Beads Approach for Screening of Functional Monoclonal Antibodies. 61
31589874 2020
30
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants. 61
32027629 2020
31
Hepatitis B Birth Dose Effects on Childhood Immunization in the U.S. 61
31959321 2020
32
Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. 61
31682981 2020
33
Bacterial, viral, and fungal infection-related risk of Parkinson's disease: Meta-analysis of cohort and case-control studies. 61
32017453 2020
34
Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data. 61
31791812 2020
35
How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers. 61
30024308 2020
36
Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. 61
32029684 2020
37
Advances in Vaccines. 61
31446443 2020
38
Functionally selective inhibition of the oxytocin receptor by retosiban in human myometrial smooth muscle. 61
31907536 2020
39
G Protein-Coupling of Adhesion GPCRs ADGRE2/EMR2 and ADGRE5/CD97, and Activation of G Protein Signalling by an Anti-EMR2 Antibody. 61
31969668 2020
40
Vaccination coverage of general practitioners: a cross-sectional study from Greece. 61
32000009 2020
41
Role of PKCζ-NADPH oxidase signaling axis in PKCα-mediated Giα2 phosphorylation for inhibition of adenylate cyclase activity by angiotensin II in pulmonary artery smooth muscle cells. 61
31965656 2020
42
Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis. 61
32007705 2020
43
Current situation, causes, and countermeasures to NIP vaccine shortages in Guangzhou, China. 61
31403888 2020
44
Temporally Coarse-Grained All-Atom Molecular Dynamics Achieved via Stochastic Padé Approximants. 61
31958947 2020
45
Family Health Days program contributions in vaccination of unreached and under-immunized children during routine vaccinations in Uganda. 61
31951608 2020
46
CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons. 61
31454418 2020
47
Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA1. 61
32007501 2020
48
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial. 61
31951771 2020
49
Midwives' knowledge, attitudes and confidence in discussing maternal and childhood immunisation with parents: A national study. 61
31628030 2020
50
Variation in Tdap and Influenza Vaccination Coverage Among Pregnant Women by Insurance Type - Florida, 2016-2018. 61
31971934 2020

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to KEGG:

36
# Name Kegg Source Accession
1 Pertussis hsa05133

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.34 TNF OPRM1 MYD88 MAPK1 JUN IL6
2
Show member pathways
14.23 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
3
Show member pathways
14.05 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
4
Show member pathways
14.01 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
5
Show member pathways
13.91 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
6
Show member pathways
13.84 TNF TLR4 MAPK10 MAPK1 JUN IL6
7
Show member pathways
13.75 TNF MAPK10 MAPK1 JUN IL6 IL1B
8
Show member pathways
13.73 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
9
Show member pathways
13.7 MAPK1 IL6 GNAZ GNAI1 GNA15 GNA14
10
Show member pathways
13.62 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
11
Show member pathways
13.59 TNF TLR4 MYD88 MAPK10 ITGB2 ITGAM
12
Show member pathways
13.57 TNF OPRM1 MYD88 MAPK1 ITGB2 ITGAM
13
Show member pathways
13.5 TNF MAPK10 MAPK1 JUN IL6 IL1B
14
Show member pathways
13.47 MAPK1 IL6 GNAZ GNAI1 GNA15 GNA14
15
Show member pathways
13.46 MAPK1 ITGB2 ITGAM GNAI1 GNA15 GNA14
16
Show member pathways
13.46 TNF MAPK10 MAPK1 JUN IL6 GNAI1
17
Show member pathways
13.44 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
18
Show member pathways
13.3 MAPK1 ITGB2 ITGAM IL6 GNAZ GNAI1
19
Show member pathways
13.29 MAPK10 MAPK1 JUN GNAZ GNAI1 GNA15
20
Show member pathways
13.29 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
21
Show member pathways
13.27 OPRM1 MAPK1 GNAZ GNAI1 GNA15 GNA14
22
Show member pathways
13.26 MAPK10 MAPK1 JUN IL6 GNAI1 GNA15
23
Show member pathways
13.25 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
24
Show member pathways
13.23 MAPK10 MAPK1 JUN GNAZ GNAI1 GNA15
25
Show member pathways
13.19 TNF MAPK10 MAPK1 JUN IL6 GNAZ
26
Show member pathways
13.19 MAPK10 JUN ITGB2 ITGAM GNAZ GNAI1
27
Show member pathways
13.16 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
28
Show member pathways
13.15 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
29
Show member pathways
13.13 MAPK10 MAPK1 JUN GNAI1 GNA15 GNA14
30
Show member pathways
13.11 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
31
Show member pathways
13.09 MAPK10 MAPK1 JUN ITGB2 GNAZ GNAI1
32 13.08 MAPK10 MAPK1 JUN IL6 GNAI1 FOS
33
Show member pathways
13.06 MAPK10 MAPK1 JUN ITGB2 ITGAM FOS
34
Show member pathways
13.04 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
35
Show member pathways
13.03 TNF ITGB2 IL6 IL1B IL10 CXCL8
36
Show member pathways
13.02 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
37
Show member pathways
13.01 MAPK1 ITGB2 ITGAM GNAI1 FOS CALM1
38
Show member pathways
12.99 TNF MYD88 MAPK10 MAPK1 JUN FOS
39 12.99 TNF MYD88 MAPK10 MAPK1 JUN IL1B
40
Show member pathways
12.98 TNF TLR4 MYD88 MAPK10 IL6 IL1B
41
Show member pathways
12.95 MAPK10 MAPK1 GNAI1 FOS CALM1 ADCY10
42
Show member pathways
12.93 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
43
Show member pathways
12.93 OPRM1 MAPK10 MAPK1 JUN GNAI1 GNA15
44
Show member pathways
12.92 TNF MAPK1 JUN IL6 FOS
45
Show member pathways
12.92 MAPK10 MAPK1 ITGB2 ITGAM GNAI1 CALM1
46
Show member pathways
12.89 TNF TLR4 MYD88 IL6 IL1B CALM1
47
Show member pathways
12.89 TNF MAPK10 MAPK1 JUN IL10 GNA15
48
Show member pathways
12.89 MAPK10 MAPK1 JUN IL1B GNAZ GNAI1
49
Show member pathways
12.87 TNF MAPK10 MAPK1 JUN IL1B FOS
50
Show member pathways
12.86 MAPK10 MAPK1 JUN FOS CALM1

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.1 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
2 membrane raft GO:0045121 9.35 TNF OPRM1 ITGB2 ITGAM GNAI1
3 transcription factor AP-1 complex GO:0035976 9.32 JUN FOS
4 integrin alphaM-beta2 complex GO:0034688 9.16 ITGB2 ITGAM
5 heterotrimeric G-protein complex GO:0005834 8.92 GNAZ GNAI1 GNA15 GNA14

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.27 OPRM1 GNAZ GNAI1 GNA15 GNA14 CXCL8
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 TNF TLR4 JUN IL6 IL1B IL10
3 positive regulation of transcription, DNA-templated GO:0045893 10.13 TNF MAPK1 JUN IL6 IL1B IL10
4 signal transduction GO:0007165 10.13 TLR4 OPRM1 MYD88 MAPK10 MAPK1 IL6
5 immune response GO:0006955 10.12 TNF TLR4 IL6 IL1B IL10 CXCL8
6 positive regulation of gene expression GO:0010628 10.09 TNF TLR4 MYD88 MAPK1 IL6 IL1B
7 negative regulation of cell proliferation GO:0008285 10.09 OPRM1 JUN IL6 IL1B IL10 CXCL8
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.03 TNF TLR4 OPRM1 JUN
9 leukocyte migration GO:0050900 10.02 TNF ITGB2 ITGAM IL1B
10 MAPK cascade GO:0000165 10.02 TNF MAPK10 MAPK1 IL1B CALM1
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10 TNF TLR4 MYD88 IL1B
12 aging GO:0007568 9.97 MAPK1 JUN ITGB2 IL10 FOS
13 Fc-epsilon receptor signaling pathway GO:0038095 9.96 MAPK10 MAPK1 JUN FOS CALM1
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
15 platelet activation GO:0030168 9.93 MAPK1 IL6 GNA15 GNA14
16 phagocytosis GO:0006909 9.91 TLR4 MYD88 ITGB2
17 activation of MAPK activity GO:0000187 9.91 TNF TLR4 MAPK10 MAPK1 IL1B
18 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
19 apoptotic signaling pathway GO:0097190 9.9 TNF TLR4 ITGAM
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 IL1B
21 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.89 OPRM1 GNAZ GNAI1
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF JUN IL6
23 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR4 MYD88 ITGB2 IL6 IL1B
24 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.87 TNF JUN IL10
25 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR4 IL1B
26 positive regulation of neuron death GO:1901216 9.85 ITGB2 ITGAM FOS
27 cellular response to reactive oxygen species GO:0034614 9.85 MAPK1 JUN FOS
28 cellular response to cadmium ion GO:0071276 9.85 MAPK1 JUN FOS
29 negative regulation of interleukin-6 production GO:0032715 9.85 TNF TLR4 IL10
30 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.85 GNAZ GNAI1 GNA15 GNA14
31 positive regulation of interleukin-6 secretion GO:2000778 9.84 TNF TLR4 IL1B
32 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.83 JUN IL10 FOS
33 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF TLR4 ITGB2 IL1B
34 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL10
35 negative regulation of neurogenesis GO:0050768 9.8 TNF IL6 IL1B
36 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 MAPK1 IL1B
37 cellular response to lipopolysaccharide GO:0071222 9.8 TNF TLR4 MYD88 IL6 IL1B IL10
38 positive regulation of chemokine production GO:0032722 9.78 TNF TLR4 IL6
39 regulation of DNA-binding transcription factor activity GO:0051090 9.78 MAPK10 MAPK1 JUN FOS
40 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
41 toll-like receptor 4 signaling pathway GO:0034142 9.77 TLR4 ITGB2 ITGAM
42 positive regulation of interleukin-6 production GO:0032755 9.77 TNF TLR4 MYD88 IL6 IL1B
43 microglial cell activation GO:0001774 9.76 TNF JUN ITGB2 ITGAM
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
45 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL10
46 negative regulation of synaptic transmission GO:0050805 9.73 IL1B GNAI1
47 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
48 positive regulation of interleukin-8 production GO:0032757 9.73 TNF TLR4 MYD88 IL1B
49 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
50 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
2 cytokine activity GO:0005125 9.65 TNF IL6 IL1B IL10 CXCL8
3 G protein-coupled receptor binding GO:0001664 9.46 GNAZ GNAI1 GNA15 GNA14
4 complement component C3b binding GO:0001851 9.37 ITGB2 ITGAM
5 G protein-coupled serotonin receptor binding GO:0031821 9.32 GNAZ GNAI1
6 G-protein beta/gamma-subunit complex binding GO:0031683 9.26 GNAZ GNAI1 GNA15 GNA14
7 guanyl nucleotide binding GO:0019001 8.92 GNAZ GNAI1 GNA15 GNA14

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....